Thursday, October 15, 2009

54 - Monoclonal antibodies approved for Hematological and Solid tumors

ANTIGEN AND TUMOR CELL TARGETS
ANTIGEN FUNCTION
NAKED ANTIBODIES
Antigen: CD20
Proliferation/differentiation
Rituximab (chimeric)
Tumor type: B-cell lymphoma and CLL
Antigen: CD52
Unknown
Alemtuzumab (humanized)
Tumor type: B-cell CLL and T-cell lymphoma
Antigen: CD25 alpha subunit
Activation antigen
Daclizumab (humanized)
Tumor type: T-cell mycosis fungoides
Antigen: CD33
Unknown
Gemtuzumab (humanized)
Tumor type: acute myeloid leukemia
Antigen: HER2/neu (ErbB-2)
Tyrosine kinase
Trastuzumab (humanized)
Tumor type: breast cancer
Antigen: EGFR (ErbB-1)
Tyrosine kinase
Cetuximab (chimeric)
Tumor type: colorectal; NSCLC; pancreatic, breast
Antigen: VEGF
Angiogenesis
Bevacizumab (humanized)
Tumor type: colorectal cancer

No comments:

Post a Comment

Subscribe Now: Feed

You are visitor number

Visitors currently online